Does the media prefer ARCT or OCS?

In the previous week, Arcturus Therapeutics had 1 more articles in the media than Oculis. MarketBeat recorded 2 mentions for Arcturus Therapeutics and 1 mentions for Oculis. Arcturus Therapeutics' average media sentiment score of 1.09 beat Oculis' score of 1.04 indicating that Arcturus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcturus Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Oculis 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ARCT or ZVRA?

In the previous week, Arcturus Therapeutics had 1 more articles in the media than Zevra Therapeutics. MarketBeat recorded 2 mentions for Arcturus Therapeutics and 1 mentions for Zevra Therapeutics. Arcturus Therapeutics' average media sentiment score of 1.09 beat Zevra Therapeutics' score of 0.93 indicating that Arcturus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcturus Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Zevra Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ARCT or SPRY?

In the previous week, ARS Pharmaceuticals had 4 more articles in the media than Arcturus Therapeutics. MarketBeat recorded 6 mentions for ARS Pharmaceuticals and 2 mentions for Arcturus Therapeutics. Arcturus Therapeutics' average media sentiment score of 1.09 beat ARS Pharmaceuticals' score of 0.67 indicating that Arcturus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcturus Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive ARS Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ARCT or ACRS?

In the previous week, Arcturus Therapeutics and Arcturus Therapeutics both had 2 articles in the media. Aclaris Therapeutics' average media sentiment score of 1.32 beat Arcturus Therapeutics' score of 1.09 indicating that Aclaris Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcturus Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Aclaris Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ARCT or DRUG?

In the previous week, Arcturus Therapeutics and Arcturus Therapeutics both had 2 articles in the media. Bright Minds Biosciences' average media sentiment score of 1.20 beat Arcturus Therapeutics' score of 1.09 indicating that Bright Minds Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcturus Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Bright Minds Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Arcturus Therapeutics (ARCT) Competitors

$6.05 -0.13 (-2.10%)

Closing price 04:00 PM Eastern

Extended Trading

$6.04 0.00 (-0.08%)

As of 04:59 PM Eastern

Compare

ARCT vs. OCS, ZVRA, SPRY, ACRS, and DRUG

Should you buy Arcturus Therapeutics stock or one of its competitors? MarketBeat compares Arcturus Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Arcturus Therapeutics include Oculis (OCS), Zevra Therapeutics (ZVRA), ARS Pharmaceuticals (SPRY), Aclaris Therapeutics (ACRS), and Bright Minds Biosciences (DRUG). These companies are all part of the "pharmaceutical products" industry.

How does Arcturus Therapeutics compare to Oculis?

Arcturus Therapeutics (NASDAQ:ARCT) and Oculis (NASDAQ:OCS) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, profitability, media sentiment, risk, dividends, earnings and institutional ownership.

Arcturus Therapeutics has higher revenue and earnings than Oculis. Oculis is trading at a lower price-to-earnings ratio than Arcturus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcturus Therapeutics	$82.03M	2.10	-$65.78M	-$2.81	N/A
Oculis	$1.45M	487.43	-$119.44M	-$2.13	N/A

Arcturus Therapeutics has a beta of 2.37, indicating that its share price is 137% more volatile than the broader market. Comparatively, Oculis has a beta of 0.44, indicating that its share price is 56% less volatile than the broader market.

Arcturus Therapeutics presently has a consensus target price of $24.25, indicating a potential upside of 300.83%. Oculis has a consensus target price of $38.33, indicating a potential upside of 214.47%. Given Arcturus Therapeutics' higher probable upside, equities research analysts clearly believe Arcturus Therapeutics is more favorable than Oculis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcturus Therapeutics	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64
Oculis	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

Arcturus Therapeutics has a net margin of -143.80% compared to Oculis' net margin of -8,460.67%. Arcturus Therapeutics' return on equity of -36.55% beat Oculis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcturus Therapeutics	-143.80%	-36.55%	-28.40%
Oculis	-8,460.67%	-56.78%	-45.62%

In the previous week, Arcturus Therapeutics had 1 more articles in the media than Oculis. MarketBeat recorded 2 mentions for Arcturus Therapeutics and 1 mentions for Oculis. Arcturus Therapeutics' average media sentiment score of 1.09 beat Oculis' score of 1.04 indicating that Arcturus Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcturus Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Oculis	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

94.5% of Arcturus Therapeutics shares are held by institutional investors. Comparatively, 22.3% of Oculis shares are held by institutional investors. 17.8% of Arcturus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Arcturus Therapeutics beats Oculis on 13 of the 17 factors compared between the two stocks.

How does Arcturus Therapeutics compare to Zevra Therapeutics?

Arcturus Therapeutics (NASDAQ:ARCT) and Zevra Therapeutics (NASDAQ:ZVRA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, risk, earnings, profitability, analyst recommendations and valuation.

Arcturus Therapeutics presently has a consensus price target of $24.25, suggesting a potential upside of 300.83%. Zevra Therapeutics has a consensus price target of $29.29, suggesting a potential upside of 129.33%. Given Arcturus Therapeutics' higher probable upside, equities analysts clearly believe Arcturus Therapeutics is more favorable than Zevra Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcturus Therapeutics	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64
Zevra Therapeutics	0 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.82

Arcturus Therapeutics has a beta of 2.37, meaning that its share price is 137% more volatile than the broader market. Comparatively, Zevra Therapeutics has a beta of 0.85, meaning that its share price is 15% less volatile than the broader market.

Zevra Therapeutics has higher revenue and earnings than Arcturus Therapeutics. Arcturus Therapeutics is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcturus Therapeutics	$82.03M	2.10	-$65.78M	-$2.81	N/A
Zevra Therapeutics	$106.47M	7.09	$83.23M	$1.99	6.42

Zevra Therapeutics has a net margin of 101.58% compared to Arcturus Therapeutics' net margin of -143.80%. Zevra Therapeutics' return on equity of 51.49% beat Arcturus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcturus Therapeutics	-143.80%	-36.55%	-28.40%
Zevra Therapeutics	101.58%	51.49%	28.86%

94.5% of Arcturus Therapeutics shares are owned by institutional investors. Comparatively, 35.0% of Zevra Therapeutics shares are owned by institutional investors. 17.8% of Arcturus Therapeutics shares are owned by company insiders. Comparatively, 2.4% of Zevra Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Arcturus Therapeutics had 1 more articles in the media than Zevra Therapeutics. MarketBeat recorded 2 mentions for Arcturus Therapeutics and 1 mentions for Zevra Therapeutics. Arcturus Therapeutics' average media sentiment score of 1.09 beat Zevra Therapeutics' score of 0.93 indicating that Arcturus Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcturus Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Zevra Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Zevra Therapeutics beats Arcturus Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Arcturus Therapeutics compare to ARS Pharmaceuticals?

Arcturus Therapeutics (NASDAQ:ARCT) and ARS Pharmaceuticals (NASDAQ:SPRY) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, media sentiment, profitability, dividends, earnings and analyst recommendations.

Arcturus Therapeutics has higher earnings, but lower revenue than ARS Pharmaceuticals. ARS Pharmaceuticals is trading at a lower price-to-earnings ratio than Arcturus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcturus Therapeutics	$82.03M	2.10	-$65.78M	-$2.81	N/A
ARS Pharmaceuticals	$84.28M	8.25	-$171.30M	-$2.01	N/A

Arcturus Therapeutics has a beta of 2.37, meaning that its share price is 137% more volatile than the broader market. Comparatively, ARS Pharmaceuticals has a beta of 0.95, meaning that its share price is 5% less volatile than the broader market.

Arcturus Therapeutics has a net margin of -143.80% compared to ARS Pharmaceuticals' net margin of -200.00%. Arcturus Therapeutics' return on equity of -36.55% beat ARS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcturus Therapeutics	-143.80%	-36.55%	-28.40%
ARS Pharmaceuticals	-200.00%	-153.61%	-60.85%

Arcturus Therapeutics currently has a consensus target price of $24.25, suggesting a potential upside of 300.83%. ARS Pharmaceuticals has a consensus target price of $28.20, suggesting a potential upside of 302.86%. Given ARS Pharmaceuticals' higher possible upside, analysts plainly believe ARS Pharmaceuticals is more favorable than Arcturus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcturus Therapeutics	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64
ARS Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, ARS Pharmaceuticals had 4 more articles in the media than Arcturus Therapeutics. MarketBeat recorded 6 mentions for ARS Pharmaceuticals and 2 mentions for Arcturus Therapeutics. Arcturus Therapeutics' average media sentiment score of 1.09 beat ARS Pharmaceuticals' score of 0.67 indicating that Arcturus Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcturus Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
ARS Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

94.5% of Arcturus Therapeutics shares are owned by institutional investors. Comparatively, 68.2% of ARS Pharmaceuticals shares are owned by institutional investors. 17.8% of Arcturus Therapeutics shares are owned by insiders. Comparatively, 33.8% of ARS Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Arcturus Therapeutics beats ARS Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

How does Arcturus Therapeutics compare to Aclaris Therapeutics?

Arcturus Therapeutics (NASDAQ:ARCT) and Aclaris Therapeutics (NASDAQ:ACRS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, dividends, valuation, risk, profitability, earnings and analyst recommendations.

In the previous week, Arcturus Therapeutics and Arcturus Therapeutics both had 2 articles in the media. Aclaris Therapeutics' average media sentiment score of 1.32 beat Arcturus Therapeutics' score of 1.09 indicating that Aclaris Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcturus Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Aclaris Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

94.5% of Arcturus Therapeutics shares are owned by institutional investors. Comparatively, 98.3% of Aclaris Therapeutics shares are owned by institutional investors. 17.8% of Arcturus Therapeutics shares are owned by company insiders. Comparatively, 4.8% of Aclaris Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Arcturus Therapeutics has a beta of 2.37, meaning that its stock price is 137% more volatile than the broader market. Comparatively, Aclaris Therapeutics has a beta of 0.76, meaning that its stock price is 24% less volatile than the broader market.

Arcturus Therapeutics presently has a consensus price target of $24.25, suggesting a potential upside of 300.83%. Aclaris Therapeutics has a consensus price target of $11.50, suggesting a potential upside of 102.46%. Given Arcturus Therapeutics' higher probable upside, equities research analysts plainly believe Arcturus Therapeutics is more favorable than Aclaris Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcturus Therapeutics	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64
Aclaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13

Aclaris Therapeutics has lower revenue, but higher earnings than Arcturus Therapeutics. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than Arcturus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcturus Therapeutics	$82.03M	2.10	-$65.78M	-$2.81	N/A
Aclaris Therapeutics	$7.83M	101.31	-$64.92M	-$0.56	N/A

Arcturus Therapeutics has a net margin of -143.80% compared to Aclaris Therapeutics' net margin of -832.58%. Arcturus Therapeutics' return on equity of -36.55% beat Aclaris Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcturus Therapeutics	-143.80%	-36.55%	-28.40%
Aclaris Therapeutics	-832.58%	-55.89%	-38.49%

Summary

Arcturus Therapeutics beats Aclaris Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Arcturus Therapeutics compare to Bright Minds Biosciences?

Arcturus Therapeutics (NASDAQ:ARCT) and Bright Minds Biosciences (NASDAQ:DRUG) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, media sentiment, earnings, analyst recommendations and dividends.

Bright Minds Biosciences has a net margin of 0.00% compared to Arcturus Therapeutics' net margin of -143.80%. Bright Minds Biosciences' return on equity of -20.58% beat Arcturus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcturus Therapeutics	-143.80%	-36.55%	-28.40%
Bright Minds Biosciences	N/A	-20.58%	-20.25%

Arcturus Therapeutics currently has a consensus target price of $24.25, suggesting a potential upside of 300.83%. Bright Minds Biosciences has a consensus target price of $143.83, suggesting a potential upside of 88.96%. Given Arcturus Therapeutics' higher probable upside, research analysts clearly believe Arcturus Therapeutics is more favorable than Bright Minds Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcturus Therapeutics	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64
Bright Minds Biosciences	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86

In the previous week, Arcturus Therapeutics and Arcturus Therapeutics both had 2 articles in the media. Bright Minds Biosciences' average media sentiment score of 1.20 beat Arcturus Therapeutics' score of 1.09 indicating that Bright Minds Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcturus Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Bright Minds Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Arcturus Therapeutics has a beta of 2.37, meaning that its stock price is 137% more volatile than the broader market. Comparatively, Bright Minds Biosciences has a beta of -5.34, meaning that its stock price is 634% less volatile than the broader market.

Bright Minds Biosciences has lower revenue, but higher earnings than Arcturus Therapeutics. Bright Minds Biosciences is trading at a lower price-to-earnings ratio than Arcturus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcturus Therapeutics	$82.03M	2.10	-$65.78M	-$2.81	N/A
Bright Minds Biosciences	N/A	N/A	-$8.74M	-$2.44	N/A

94.5% of Arcturus Therapeutics shares are owned by institutional investors. Comparatively, 40.5% of Bright Minds Biosciences shares are owned by institutional investors. 17.8% of Arcturus Therapeutics shares are owned by insiders. Comparatively, 42.7% of Bright Minds Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Bright Minds Biosciences beats Arcturus Therapeutics on 8 of the 14 factors compared between the two stocks.

Get Arcturus Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ARCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ARCT vs. The Competition

Export

Metric	Arcturus Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$175.65M	$3.69B	$6.90B	$12.43B
Dividend Yield	N/A	2.16%	2.67%	9.36%
P/E Ratio	-2.15	11.17	22.35	21.47
Price / Sales	2.10	304.49	526.66	91.08
Price / Cash	N/A	142.33	51.46	60.07
Price / Book	0.80	8.26	10.69	6.18
Net Income	-$65.78M	$23.83M	$3.59B	$331.73M
7 Day Performance	-13.20%	-3.47%	-2.17%	-2.29%
1 Month Performance	-17.80%	3.44%	2.08%	-1.62%
1 Year Performance	-55.32%	44.52%	24.68%	16.81%

Arcturus Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ARCT Arcturus Therapeutics	2.4272 of 5 stars	$6.05 -2.1%	$24.25 +300.8%	-51.9%	$175.65M	$82.03M	N/A	180	Positive News
OCS Oculis	3.2732 of 5 stars	$13.15 -3.5%	$38.33 +191.5%	-29.4%	$790.33M	$1.45M	N/A	2	Positive News
ZVRA Zevra Therapeutics	4.2502 of 5 stars	$13.18 -1.3%	$29.29 +122.2%	+3.6%	$789.19M	$106.47M	6.62	20
SPRY ARS Pharmaceuticals	3.2732 of 5 stars	$7.74 -2.5%	$28.20 +264.3%	-58.3%	$788.47M	$84.28M	N/A	90	Gap Down
ACRS Aclaris Therapeutics	3.0877 of 5 stars	$5.50 -1.4%	$11.50 +109.1%	+239.2%	$779.32M	$7.83M	N/A	100	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ARCT) was last updated on 7/17/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Arcturus Therapeutics (ARCT) Competitors

ARCT vs. OCS, ZVRA, SPRY, ACRS, and DRUG

How does Arcturus Therapeutics compare to Oculis?

Summary

How does Arcturus Therapeutics compare to Zevra Therapeutics?

Summary

How does Arcturus Therapeutics compare to ARS Pharmaceuticals?

Summary

How does Arcturus Therapeutics compare to Aclaris Therapeutics?

Summary

How does Arcturus Therapeutics compare to Bright Minds Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARCT vs. The Competition

Arcturus Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Arcturus Therapeutics (ARCT) Competitors

ARCT vs. OCS, ZVRA, SPRY, ACRS, and DRUG

How does Arcturus Therapeutics compare to Oculis?

Which has stronger earnings & valuation, ARCT or OCS?

Which has more volatility & risk, ARCT or OCS?

Do analysts rate ARCT or OCS?

Is ARCT or OCS more profitable?

Does the media prefer ARCT or OCS?

Do institutionals & insiders hold more shares of ARCT or OCS?

Summary

How does Arcturus Therapeutics compare to Zevra Therapeutics?

Do analysts rate ARCT or ZVRA?

Which has more volatility and risk, ARCT or ZVRA?

Which has stronger earnings & valuation, ARCT or ZVRA?

Is ARCT or ZVRA more profitable?

Do institutionals and insiders hold more shares of ARCT or ZVRA?

Does the media favor ARCT or ZVRA?

Summary

How does Arcturus Therapeutics compare to ARS Pharmaceuticals?

Which has better valuation & earnings, ARCT or SPRY?

Which has more risk & volatility, ARCT or SPRY?

Is ARCT or SPRY more profitable?

Do analysts rate ARCT or SPRY?

Does the media refer more to ARCT or SPRY?

Do institutionals & insiders hold more shares of ARCT or SPRY?

Summary

How does Arcturus Therapeutics compare to Aclaris Therapeutics?

Does the media refer more to ARCT or ACRS?

Do insiders & institutionals hold more shares of ARCT or ACRS?

Which has more volatility & risk, ARCT or ACRS?

Do analysts rate ARCT or ACRS?

Which has higher valuation and earnings, ARCT or ACRS?

Is ARCT or ACRS more profitable?

Summary

How does Arcturus Therapeutics compare to Bright Minds Biosciences?

Is ARCT or DRUG more profitable?

Do analysts rate ARCT or DRUG?

Does the media refer more to ARCT or DRUG?

Which has more volatility and risk, ARCT or DRUG?

Which has preferable earnings & valuation, ARCT or DRUG?

Do insiders and institutionals hold more shares of ARCT or DRUG?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARCT vs. The Competition

Arcturus Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools